Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Patil Neena M | EVP & Chief Legal Officer | May 03 '24 | Sale | 109.65 | 5,000 | 548,250 | 36,629 | May 07 05:31 PM | Carr Patricia | SVP, Chief Accounting Officer | Mar 07 '24 | Sale | 116.98 | 1,768 | 206,821 | 6,596 | Mar 08 06:07 PM | Carr Patricia | SVP, Chief Accounting Officer | Mar 06 '24 | Sale | 119.64 | 1,936 | 231,628 | 8,364 | Mar 08 06:07 PM | Johnson Philip L | EVP & Chief Financial Officer | Mar 01 '24 | Buy | 119.65 | 12,000 | 1,435,800 | 27,932 | Mar 05 07:28 PM | Cook Jennifer E. | Director | Dec 04 '23 | Sale | 119.27 | 417 | 49,736 | 6,888 | Dec 06 04:31 PM | Smith Mark Douglas | Director | Dec 04 '23 | Sale | 119.27 | 417 | 49,736 | 6,888 | Dec 06 04:39 PM | Patil Neena M | EVP & Chief Legal Officer | Sep 01 '23 | Sale | 144.25 | 1,500 | 216,375 | 29,186 | Sep 06 05:09 PM | Carr Patricia | SVP, Chief Accounting Officer | Aug 29 '23 | Sale | 143.47 | 142 | 20,373 | 5,986 | Aug 31 06:44 PM | Patil Neena M | EVP & Chief Legal Officer | Aug 15 '23 | Sale | 139.59 | 750 | 104,695 | 30,686 | Aug 17 05:21 PM | McSharry Heather Ann | Director | Aug 14 '23 | Sale | 138.16 | 1,344 | 185,685 | 16,778 | Aug 15 05:52 PM | Sohn Catherine A. | Director | Aug 14 '23 | Sale | 138.16 | 1,241 | 171,455 | 14,868 | Aug 15 06:02 PM | ENRIGHT PATRICK G | Director | Aug 14 '23 | Sale | 138.16 | 1,241 | 171,455 | 20,946 | Aug 15 05:45 PM | O'Keefe Kenneth W | Director | Aug 14 '23 | Sale | 138.16 | 1,241 | 171,455 | 24,723 | Aug 15 07:49 PM | Winningham Rick E | Director | Aug 14 '23 | Sale | 138.16 | 1,241 | 171,455 | 10,444 | Aug 15 06:08 PM | Gray Peter | Director | Aug 14 '23 | Sale | 138.16 | 1,241 | 171,455 | 16,068 | Aug 15 05:47 PM | Cook Jennifer E. | Director | Aug 14 '23 | Sale | 138.16 | 1,241 | 171,454 | 7,305 | Aug 15 05:44 PM | RIEDEL NORBERT G | Director | Aug 14 '23 | Sale | 138.16 | 1,241 | 171,454 | 13,705 | Aug 15 05:58 PM | ORiordan Anne | Director | Aug 14 '23 | Sale | 138.16 | 1,241 | 171,454 | 12,551 | Aug 15 07:51 PM | Smith Mark Douglas | Director | Aug 14 '23 | Sale | 138.16 | 1,241 | 171,454 | 7,305 | Aug 15 06:00 PM | Carr Patricia | SVP, Chief Accounting Officer | Aug 14 '23 | Sale | 138.16 | 158 | 21,829 | 6,128 | Aug 15 05:43 PM | Mulligan Seamus | Director | Jun 08 '23 | Option Exercise | 81.76 | 4,500 | 367,920 | 1,169,300 | Jun 12 04:47 PM | Carr Patricia | SVP, Chief Accounting Officer | Jun 07 '23 | Sale | 127.92 | 126 | 16,117 | 6,286 | Jun 09 04:55 PM | Patil Neena M | EVP & Chief Legal Officer | Jun 01 '23 | Sale | 127.98 | 1,600 | 204,763 | 32,826 | Jun 05 08:24 PM | GALA RENEE D | EVP & Chief Financial Officer | May 18 '23 | Sale | 131.75 | 6,000 | 790,474 | 35,978 | May 19 08:45 PM |
|